ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · HP_0100607

Dysmenorrhea

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. Dysmenorrhea. Diseases, record HP_0100607. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0100607

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
Dysmenorrhea
Open Targets ID
HP_0100607
Other names
Painful menstruation
Highest stage of its drugs
Approval, for 22 of its 44 drugs, from DailyMed, FDA, PMDA and TTD

Source Open Targets

Drugs44

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
ETHINYL ESTRADIOLCHEMBL691Small moleculeApprovalPMDA191614Drugs and targets
DROSPIRENONECHEMBL1509Small moleculeApprovalPMDA1187Drugs and targets
IBUPROFENCHEMBL521Small moleculeApprovalDailyMed15964Drugs and targets
NAPROXENCHEMBL154Small moleculeApprovalDailyMed1453Drugs and targets
NORETHINDRONECHEMBL1162Small moleculeApprovalPMDA644Drugs and targets
DIENOGESTCHEMBL1201864Small moleculeApprovalPMDA544Drugs and targets
LEVONORGESTRELCHEMBL1389Small moleculeApprovalPMDA543Drugs and targets
NAPROXEN SODIUMCHEMBL1200806Small moleculeApprovalDailyMed and FDA6033Drugs and targets
MEFENAMIC ACIDCHEMBL686Small moleculeApprovalDailyMed and TTD1022Drugs and targets
ACETAMINOPHENCHEMBL112Small moleculeApprovalDailyMed422Drugs and targets

1 to 10 of 44

See all 44 drugs

Targets28

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
PTGS2Cyclooxygenase14Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitorApprovalhttps://conductscience.org/library/genes/5743Drugs and targets
PTGS1Cyclooxygenase11Cyclooxygenase inhibitorApprovalhttps://conductscience.org/library/genes/5742Drugs and targets
PGRProgesterone receptor7Progesterone receptor agonist; Progesterone receptor antagonistApprovalhttps://conductscience.org/library/genes/5241Drugs and targets
ESR1Estrogen receptor3Estrogen receptor alpha agonistApprovalhttps://conductscience.org/library/genes/2099Drugs and targets
HTR1B5-hydroxytryptamine receptor 1B2Serotonin 1b (5-HT1b) receptor agonistPhase 3https://conductscience.org/library/genes/3351Drugs and targets
HTR1D5-hydroxytryptamine receptor 1D2Serotonin 1d (5-HT1d) receptor agonistPhase 3https://conductscience.org/library/genes/3352Drugs and targets
NR3C1Glucocorticoid receptor2Glucocorticoid receptor agonist; Glucocorticoid receptor antagonistPhase 3https://conductscience.org/library/genes/2908Drugs and targets
ALOX5Polyunsaturated fatty acid 5-lipoxygenase1Arachidonate 5-lipoxygenase inhibitorApprovalhttps://conductscience.org/library/genes/240Drugs and targets
AVPR1AVasopressin V1a receptor1Vasopressin V1a receptor antagonistPhase 1https://conductscience.org/library/genes/552Drugs and targets
FAAHFatty-acid amide hydrolase 11Anandamide amidohydrolase inhibitorApprovalhttps://conductscience.org/library/genes/2166Drugs and targets

1 to 10 of 28

See all 28 targets

Trials45

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT00909857Effect on Primary DysmenorrheaPhase 35072012-02-27Primary DysmenorrheaDIENOGEST, ESTRADIOL VALERATE, ETHINYL ESTRADIOL, LEVONORGESTRELOpen Targets' reading of its recordClinicalTrials.gov
NCT01670656A Study to Evaluate the Effect of Contraceptive Vaginal Rings on Primary Dysmenorrhea (P08257/MK-8175A/MK-8342B-057)Phase 24392017-08-24DysmenorrheaETONOGESTREL, NOMEGESTROL ACETATEIts record names the diseaseClinicalTrials.gov
NCT00461305Safety Study of Ethinylestradiol/Drospirenone in DysmenorrheaPhase 2/34202010-10-01DysmenorrheaDROSPIRENONE, ETHINYL ESTRADIOLIts record names the diseaseClinicalTrials.gov
NCT00511797SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative StudyPhase 2/32492010-10-04DysmenorrheaDROSPIRENONEIts record names the diseaseClinicalTrials.gov
NCT01129102Efficacy and Safety Study of NPC-01 to Treat DysmenorrheaPhase 32152014-06-17DysmenorrheaETHINYL ESTRADIOL, NORETHINDRONEIts record names the diseaseClinicalTrials.gov
NCT00902746Efficacy and Safety, Long-Term Study of NPC-01 to Treat Dysmenorrhea Associated With EndometriosisPhase 31492014-06-13DysmenorrheaETHINYL ESTRADIOL, NORETHINDRONEIts record names the diseaseClinicalTrials.gov
NCT00951561A Comparison Study of Pain Relief From Dysmenorrhea Between the Vipon Tampon and IbuprofenNot applicable1152010-10-04DysmenorrheaIBUPROFENIts record names the diseaseClinicalTrials.gov
NCT00984815Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug TreatmentPhase 3862013-07-25Osteoarthritis, Rheumatoid Arthritis, Chronic Low Back Pain, Chronic Regional Pain Syndrome, Chronic Soft Tissue PainFAMOTIDINE, IBUPROFENIts record names the diseaseClinicalTrials.gov
NCT00651313Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods)Phase 2812011-07-06DysmenorrheaLIDOCAINEIts record names the diseaseClinicalTrials.gov
NCT00517556Continuous Administration of Oral Contraceptive, Primary DysmenorrheaPhase 1/2382017-04-28DysmenorrheaETHINYL ESTRADIOLIts record names the diseaseClinicalTrials.gov

1 to 10 of 45

See all 45 trials

Comparisons in its trials12

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027) vs Ethinyl Estradiol, Levonorgestrel (Miranova): serious adverse events2 of 2342 of 230464NCT00909857Trial comparisons
DRSP 3 mg/EE 20 µg (13 Cycles) vs DRSP 3 mg/EE 30 µg (6 Cycles): serious adverse events5 of 3550 of 65420NCT00461305Trial comparisons
DRSP 3 mg/EE 20 µg (6 Cycles) vs DRSP 3 mg/EE 30 µg (6 Cycles): Number of Participants With Intracyclic Bleeding at Cycle 640 of 2994 of 56355NCT00461305Trial comparisons
Active vs Placebo: serious adverse events0 of 770 of 77154NCT00651313Trial comparisons
Study Group (CCOCP) vs Control Group (Traditional OCP): deaths from any cause0 of 190 of 1938NCT00517556Trial comparisons
Study Group (CCOCP) vs Control Group (Traditional OCP): serious adverse events0 of 190 of 1938NCT00517556Trial comparisons
ENG-E2 125 μg/300 μg vs Placebo: Number of Participants Who Experienced an Adverse Event (AE)1 of 132 of 1124NCT02668783Trial comparisons
ENG-E2 125 μg/300 μg vs Placebo: Number of Participants Who Discontinued Treatment Due to an AE0 of 130 of 1124NCT02668783Trial comparisons
ENG-E2 125 Microgram/300 Microgram vs Placebo: serious adverse events0 of 130 of 1124NCT02668783Trial comparisons
ENG 125 μg + E2 300 μg (MK-8342B) vs Placebo: Number of Participants Who Discontinued Study Treatment Due to an AE0 of 90 of 918NCT02668822Trial comparisons

1 to 10 of 12

See all 12 comparisons in its trials

Papers from its trials32

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
35123042RESULT1PubMed
34961515RESULT1PubMed
33590656RESULT1PubMed
32767677RESULT1PubMed
29845696RESULT1PubMed
24108307RESULT1PubMed
22454006RESULT1PubMed
21955195RESULT1PubMed
20353434RESULT2PubMed
19546766RESULT2PubMed

1 to 10 of 32

See all 32 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0100607

GET https://conductscience.org/api/diseases/v1/HP_0100607/drugs?page=2

API referenceFor AI assistants